Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients

Acta Oncologica

Volumn 37, Issue 2, 1998, Pages 187-191

  Carles, Joan ^a,f   Domenech, Montserrat ^b   Gelabert Mas, Antonio ^a   Nogue, Miquel ^c   Tabernero, Josep M ^d   Arcusa, Angeles ^e   Guasch, Inmaculada ^b   Miguel, Ana ^a   Ballesteros, Juan J ^a   Fabregat, Xavier ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Oncology Unit   (Spain)

^c HOSPITAL DE SABADELL   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e TERRASSA HEALTH CONSORTIUM   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE; NAVELBINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HORMONAL REGULATION; HORMONE RESISTANCE; HUMAN; MALE; MICROTUBULE ASSEMBLY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 7144227298     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698429757     Document Type: Article

References (18)

1. Crawford DE. Prostate cancer screening. Educational book. 32nd Annual Meeting. Philadelphia. Am Soc Clin Oncol 1996, 119-24.
2. Klein LA. Prostatic carcinoma. N Engl J Med 1968; 300: 26-33.
3. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098-109.
4. Stears Me, Wang M, Tew K, Binder LI. Estramustine binds a MAP-1 like protein to inhibit microtubule assembly in vitro and disrupts microtubule organization in DU 145 cells. J Cell Biol 1988; 107: 2647-52.
5. Cannobio L, Boccardo F, Pastorino G, et al. Phase II study of navelbine in advanced breast cancer. Semin Oncol 1989; 16 (Suppl 4): 33-6.
6. Coltman CA, Vinorelbine. A new agent for the treatment of non-small cell lung cancer. A summary. Semin Oncol 1994; 21 (Suppl 10): 1-3.
7. Donehower RC, Rowinsky EK. Anticancer drugs derived from plants. In: De Vita VT, Hellman S, Rosenberg, eds. Cancer. Principles and practice of oncology. 4th edition. Philadelphia: JB Lippincott Co., 1993; 409-17.
8. Seidman AD, Scher HI, Petrylak D, Dershaw D, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992; 147: 931-4.
9. Speicher LA, Barone L, Tew K. Combined anlimicrotubule activity or estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992; 52: 4433-40.
10. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormonorefractory prostate cancer. J Clin Oncol 1997; 15: 3156-63.
11. Pienta KJ, Redman BG, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-12.
12. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
13. Dawson NA, Cooper M, Figg WD. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995; 76: 453-62.
14. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen independent prostate cancer. J Clin Oncol 1994; 12: 683-8.
15. De Kernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostate cancer. Urology 1988; 149: 1622-5.
16. Tew KD, Stearns ME. Hormone-independent, non-alkylating mechanism of cytotoxicity of estramustine. Urol Res 1987; 15: 155-60.
17. Rutberg M, Friden B, Bjork P, et al. Proteolytic cleavage of high molecular weight microtubule associated proteins by the prostatic estramustine binding protein. Prostate 1989; 15: 287-97.
18. Attivissimo LA, Fetten JV, Kreis WK. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol 1996; 19: 581-3.